PharmaTimes article: Overcoming Barriers to Care Using AI
Artificial intelligence (AI) can be used to optimize home-based care, easing provider burden in sites that struggle with capacity.
Telehealth in Medicare: Shifts Before and After COVID-19
Pandemic-era telehealth flexibilities in Medicare will expire in April 2025, potentially limiting primary care access for beneficiaries.
Opportunities to Move the Needle on US Behavioral Healthcare in 2025
Behavioral health is at a turning point in 2025, with newly implemented policies, groundbreaking treatments, and novel regulatory and financial dynamics.
Highlights From The 2024 InformaConnect Congress
Two Avalere experts captured information presented at a recent conference and published their perspectives in Pharmaceutical Commerce.
Avalere Covered in Nephrology News
With nearly 4,000 posters presented at ASN’s annual conference, Avalere’s study of post-COVID home dialysis stands apart with a feature in Nephrology News.
Health Policy Veteran Emily Donaldson Joins Avalere
Emily Donaldson brings 15 years of experience supporting pharmaceutical manufacturers and health plans, focused on insurance markets and state healthcare policy.
Health Policy in the 2024 Election: Avalere and Outside Experts Weigh In
With the election fast approaching, former HHS Secretary Alex Azar, Dan Mendelson, and Avalere experts discussed implications for healthcare stakeholders.
An Access Path for Digital Therapeutics
Based on Brigit Kyei-Baffour’s panel presentation at BIO 2024, Med Ad News published a summary of the insights from participants.
A Deep Dive Into Hospice Utilization Trends
Avalere analysis reveals an opportunity to support more Medicare beneficiaries with hospice care, as evolving diagnoses and ALOS prompt reevaluation of program metrics
BIO International Convention Insights: Patient Assistance and Digital Therapeutics
At the 2024 BIO International Convention, Avalere led discussions on post-IRA patient access and affordability and reimbursement pathways for digital therapeutics.
Addressing Sex and Gender Disparities in Cognitive Health
Women are more likely to experience reduced cognitive health later in life. Recent federal efforts seek to address the paucity of research on this phenomenon.
How is FemTech Driving Innovation in Women’s Health?
FemTech is redefining women’s health. See how technology is powering new solutions in wellness, diagnostics, and reproductive care.
Mitigating and Preventing Drug Shortages
Avalere experts provide insights on the dynamics and policy proposals surrounding recent drug shortages.
FDA Supply Chain and Quality Balancing Act: What’s Next?
The industry should expect and prepare for changes to regulatory oversight of drug supply chains and quality.
Court Ruling Will Limit Accumulators
A district court’s decision to strike down the 2021 NBPP is the latest policy update on the use of copay adjustment programs, but questions persist.
How Did Public Comments Shape Revised Negotiation Guidance?
Comments on initial negotiation guidance significantly shaped the revised guidance, underscoring the importance of stakeholder engagement in IRA implementation.
How Do IRA Drug Pricing Policies Interact with One Another?
Stakeholders should consider the interaction of inflation-based rebates, AMP cap removal, and Medicare price negotiation in pricing and contracting strategies.
Hospital at Home: Opportunities for Manufacturers and Digital Health
The COVID-19 public health emergency and advancements in digital health technologies accelerated the adoption of Hospital at Home, a promising acute-care delivery model.
Insights on IRA Policies and Business Impacts Presented at Asembia
Avalere’s expert presentations at the AXS23 Summit described IRA drug-pricing policies and the law’s impact on patient access and affordability.
Digital Health Technology Access Requires Early FDA, Payer Engagement
As digital health technologies evolve, manufacturers seek clarity on regulatory pathways and access channels.